Mufg Securities Emea Plc adds Gilead Sciences (GILD) to its portfolio

Gilead Sciences (GILD) : Mufg Securities Emea Plc added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 9,670 shares of Gilead Sciences which is valued at $770,312 , the company said in a statement filed on Aug 11, 2016 with the SEC.Gilead Sciences makes up approximately 3.20% of Mufg Securities Emea Plc’s portfolio.

Other Hedge Funds, Including , Sunbelt Securities boosted its stake in GILD in the latest quarter, The investment management firm added 518 additional shares and now holds a total of 4,302 shares of Gilead Sciences which is valued at $342,697. Gilead Sciences makes up approx 0.34% of Sunbelt Securities’s portfolio.Ardevora Asset Management Llp boosted its stake in GILD in the latest quarter, The investment management firm added 71,700 additional shares and now holds a total of 322,700 shares of Gilead Sciences which is valued at $25,677,239. Gilead Sciences makes up approx 1.02% of Ardevora Asset Management Llp’s portfolio.Bb&t Securities boosted its stake in GILD in the latest quarter, The investment management firm added 250,591 additional shares and now holds a total of 612,262 shares of Gilead Sciences which is valued at $49,231,987. Gilead Sciences makes up approx 0.74% of Bb&t Securities’s portfolio. Spinnaker Trust sold out all of its stake in GILD during the most recent quarter. The investment firm sold 13,209 shares of GILD which is valued $1,057,909.Concorde Asset Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,053 additional shares and now holds a total of 4,708 shares of Gilead Sciences which is valued at $407,477. Gilead Sciences makes up approx 0.39% of Concorde Asset Management’s portfolio.

Gilead Sciences opened for trading at $81.46 and hit $81.64 on the upside on Tuesday, eventually ending the session at $81.47, with a gain of 0.68% or 0.55 points. The heightened volatility saw the trading volume jump to 82,79,418 shares. Company has a market cap of $107,513 M.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *